Location: United States, Ohio, Columbus
Employees: 1-10
Total raised: $44.2M
Founded date: 2014
Investors 1
| Date | Name | Website |
| 02.11.2022 | Xontogeny | xontogeny.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.11.2021 | - | $40M | Xontogeny |
| 28.11.2017 | Seed | $4.2M | - |
Mentions in press and media 10
| Date | Title | Description |
| 24.03.2025 | Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics | Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical co... |
| 28.04.2022 | Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | COLUMBUS, Ohio, April 28, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, ... |
| 13.12.2021 | Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium | COLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, t... |
| 13.12.2021 | Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium | Poster describes pre-clinical findings that lasofoxifene alone or in combination with a CDK inhibitor may limit tumor progression in aromatase inhibitor (AI) resistant tumors not resistant due to an ESR1 mutation COLUMBUS, Ohio, Dec. 13, 20... |
| 13.12.2021 | Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium | COLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, t... |
| 29.11.2021 | Sermonix Pharmaceuticals Raises $40M in Series A3 Funding | Sermonix, a Columbus OH-based biopharmaceutical company, raised $40M in Series A3 funding. The round was led by Perceptive Xontogeny Ventures Fund II (PXV Fund) with participation from existing investors. As part of the agreement, Fred Call... |
| 15.11.2021 | Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II | Funds will be used to further advance lasofoxifene through late-stage clinical development as a next-generation oral SERM to treat women with increasingly prevalent ESR1 breast cancer mutations Initial data from both Phase 2 clinical trials... |
| 15.11.2021 | Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II | Funds will be used to further advance lasofoxifene through late-stage clinical development as a next-generation oral SERM to treat women with increasingly prevalent ESR1 breast cancer mutations Initial data from both Phase 2 clinical trials... |
| 17.05.2021 | Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer | Paper highlights the ability of lasofoxifene to inhibit primary tumor growth and reduce metastases in mouse models, both as monotherapy and in combination with palbociclib Study results demonstrate potential of lasofoxifene as a next-genera... |
| 28.11.2017 | Sermonix Pharmaceuticals Completes $4.2M Seed Financing | Sermonix Pharmaceuticals, a Columbus, OH-based biotechnology company focused on the development and commercialization of female-specific oncology products, completed a $4.2m seed financing. Backers included new investors Richard DeSchutter,... |